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The STARD1 subfamily of ‘START’ lipid trafﬁcking proteins can reduce macrophage lipid content and
inﬂammatory status (STARD1; StAR), and trafﬁc cholesterol from endosomes (STARD3/MLN64). Dur-
ing macrophage differentiation, STARD1 mRNA and protein increase with sterol content, while the
reverse is true for STARD3. Sterol depletion (methyl beta-cyclodextrin) enhances STARD3, and
represses STARD1 expression. Agonists of Liver X receptors, peroxisome proliferator activated recep-
tor-gamma and retinoic acid X receptors increase STARD1 expression, while hypocholesterolaemic
agent, LY295427, reveals both STARD1 and STARD3 as putative SREBP-target genes. Pathophysiolog-
ical ‘foam cell’ formation, induced by acetylated or oxidized LDL, signiﬁcantly reduced both STARD1
and STARD3 gene expression. Differential regulation of STARD1 and D3 reﬂects their distinct roles in
macrophage cholesterol metabolism, and may inform anti-atherogenic strategies.
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Dysregulation of macrophage cholesterol homeostasis lies at
the heart of developing atherosclerotic lesions [1]. Macrophage
‘foam cells’, laden with cholesterol and cholesteryl ester, result
from the unregulated uptake of pro-atherogenic lipoproteins, such
as oxidized low-density lipoprotein (OxLDL) via macrophage scav-
enger receptors, and are a hallmark of early atheroma, inﬂuencing
both plaque stability and progression [2]. Elimination of choles-
terol from macrophage foam cells can be achieved, in vitro and
in vivo, by cellular cholesterol efﬂux orchestrated by ATP-binding
cassette (ABC) transporters, such as ABCA1 and ABCG1, and ‘accep-
tor’ apolipoproteins such as apoAI, apoE and high-density lipopro-
teins (HDL) [3]. Efﬁcient intracellular lipid transport is increasingly
recognized to be pivotal to cellular sterol homeostasis, inﬂuencing
the activity of lipid and sterol-sensitive transcription factors, such
as sterol regulatory element binding proteins (SREBPs), liver X
receptors (LXR), peroxisome proliferator activated receptors
(PPARs) and retinoic acid X receptors (RXR) [4], regulating the ste-on behalf of the Federation of Euro
).rol content of organelles, lipid rafts and membranes, and control-
ling the formation of cytosolic droplets of cholesteryl ester [5].
Recent work implicates proteins containing steroidogenic
acute regulatory protein (StAR)-related lipid transfer (START) do-
mains in non-vesicular lipid transport, cell signaling events and,
most recently, cellular cholesterol homeostasis [6,7]. The START
domain is a 210 amino acid region which provides a hydrophobic
lipid binding pocket for various lipids, including cholesterol, oxys-
terols, phospholipid and ceramides [6,7]. In particular, START do-
mains of the STARD1 subfamily of lipid trafﬁcking proteins (StAR/
STARD1 and its closest relative STARD3/MLN64), exhibit a high
afﬁnity for cholesterol [8]. StAR, the prototypic member of this
family, plays an established role in mitochondrial cholesterol
transport in steroidogenic tissues, facilitating delivery of choles-
terol to the inner mitochondrial membrane, wherein P450 side
chain cleavage enzyme (P450scc) resides, generating pregneno-
lone [9,10]. Recent data identiﬁed StAR in human and murine
macrophages [11], where it is thought to trafﬁck cholesterol to
mitochondrial sterol 27-hydroxylase (CYP27A1), generating oxy-
sterol ligands for LXR, and reducing macrophage lipid mass and
inﬂammatory status [12]. By contrast, STARD3 is endosomally lo-
cated, where it may act in concert with Niemann Pick C1 (NPC1)pean Biochemical Societies.
1148 F. Borthwick et al. / FEBS Letters 583 (2009) 1147–1153and NPC2 proteins [13]; over-expression of STARD3 in cultured
cells leads to enlargement of late endosomes, possibly via actin-
dependent endosomal fusion, while depletion of STARD3 results
in the dispersal of late endocytic vesicles, displaying decreased
actin association [14].
However, despite their potential importance, regulation of
these cholesterol-trafﬁcking proteins in macrophages and macro-
phage ‘foam cells’ remains poorly understood. In this study, we
investigate the regulation of STARD1 and STARD3 during macro-
phage differentiation, sterol depletion, ‘foam cell’ formation, in re-
sponse to LXR, PPAR and RXR agonists and following the addition
of hypocholesterolaemic agent, LY295427.
2. Methods
2.1. Macrophage experiments
Human (THP-1) monocytes (ECACC 880812101) were main-
tained and differentiated into macrophages (1.5  106 well1) by
the addition of phorbol ester (phorbol 12-myristate 13-acetate;
Sigma–Aldrich, Dorset, UK) for up to 7 days, in RPMI 1640 medium
containing fetal bovine serum (FBS, 10%, v/v) (Lonza, Wokingham,
UK), as previously described [15]. Cellular lipids, RNA and cell pro-
tein lysates were collected on days 0, 1, 2, 4 and 7 of differentia-
tion. Cholesterol depletion was achieved by acute treatment with
methyl b-cyclodextrin (10 mM, 1 h), with cellular samples col-
lected 24 h after sterol depletion. Macrophages were cholesterol
loaded by treatment with acetylated or oxidized LDL (50 lg ml1;
48 h) in serum-free RPMI 1640 medium [15]. Treatment
(24 h) with lovastatin (10 lM), LXR (T901317; 10 lM), RXR (9-
cis-retinoic acid, 5 lM), PPARa (GW7647, 10 lM), PPARc
(GW1929; 10 lM) and PPARd (GW0742; 10 lM) agonists were
made in DMSO (<0.1% vehicle); addition of LY295427 (20 lM)
was made in ethanol (<0.1% vehicle).
2.2. Lipid analyses
Incorporation of [14C]acetic acid (1 lCi ml1) into fatty acid,
phospholipid, cholesterol, cholesteryl ester and triacylglycerol
pools were measured after incubation for 24 h. Macrophage lipids
were extracted using hexane: isopropanol (3:2, v/v), dried under
N2, and resuspended in isopropanol, before separation by t.l.c.,
using chloroform, methanol and water (60:30:5, v/v/v) as the mo-
bile phase in the ﬁrst development, and hexane, diethyl ether and
acetic acid (80:20:1.5, v/v/v) in the second phase of development.
Lipids were identiﬁed by co-migration with authentic standards,
and incorporation of radiolabel assessed by scintillation counting.
Results are expressed as nmol radiolabel incorporated mg1 cell
protein. Mass of macrophage triacylglycerol, cholesterol and cho-
line-containing phospholipids were made using InﬁnityTM and
Phospholipids-B (Alpha Labs) colorimetric assays, and visualized
by Oil-Red-O staining. Efﬂux of [3H] cholesterol to apoAI
(10 lg ml1), and measurement of cellular ABCA1 protein levels,
were measured exactly as previously described, except that a mur-
ine monoclonal antibody to ABCA1 (AbCAM) was utilized [15].
2.3. Relative expression of STARD1 and STARD3 mRNA and protein
Total RNA (Tri-Reagent, Sigma–Aldrich) was isolated from mac-
rophages (above) and reverse transcribed to cDNA using the MMLV
reverse transcriptase (RT) enzyme (BioLine). Polymerase chain reac-
tions (PCR) was utilized to generate amplicons for sequencing (MRC
Dundee) using exon-spanning primers based on sequences derived
from NIH GenBank: STARD1 (forward 50-actcagaggcaagcctgag-30;
reverse 50-cagccctcttggttgctaag-30); STARD3 (forward 50-agcgagtg-
gaagacaacacc-30; reverse 50-catcaacaggccagacc-30). Expression ofSTARD1, STARD3, ABCA1, PPARG, RXR, LXR, SREBP-1 and SREBP-2
mRNA, relative to the housekeeping gene, GAPDH, was performed
by quantitative (real time) ‘Taqman’ PCR, using a DNA Engine Opti-
con2 (MJResearch). PCR reactions contained600 ng cDNA template,
absolute Q-PCR mix (ThermoFisher Scientiﬁc, UK), molecular biol-
ogy grade water (Sigma–Aldrich) and 100 nM each forward and re-
verse primers, and 100 nM probe. Thermal cycling conditions were
15 min at 95 C, followed by 40 cycles of 15 s at 95 C and 20 s at
60 C, stasis at 50 C. Probes containing FAM as 50-reporter, TAMRA
as 30-quencher, and oligonucleotide primers (Eurogentec, S.A., Bel-
gium), were designed using PrimerExpress Software (PE Applied
Biosystems, UK), using the human coding sequences available from
NIH GenBank, and according to the following details: STARD1 (for-
ward 50-gaagaaccacccttgagagaagaf-30; reverse 50-gtcgctagcag-
cattgtttcc-30; probe50-cggcagcgaccccaccactg-30), STARD3 (forward
50-cctgccccggtacctcat-30; reverse 50-gcgctgtcgcaggtgaa-30; probe 50-
agagcctcgcggccaccatgt-30), ABCA1 (forward 50-tgtccagtccag-
taatggttctgt-30; reverse 50-aagcagagatatggtccggat-30; probe 50-aca-
cctggaga gaagctttcaacgagactaacc-30), PPARG (forward 50-
ggtggccatccgcatct-30; reverse 50-gcttttggcatactctgt gatctc-30; probe
50-tcagggctgccagtttcgctcc-30), RXR (forward 50-tgtttccgttgctgtttatc-
gat-30; reverse 50-cagtattcagagcagatgaagatgtca-30; probe 50-
tcctgtgtggccctcctgtctgga-30), LXR (forward 50-gaaacaa ctgggcatgatc-
ga-30; reverse 50-aaggagcgccggttacact-30; probe 50-aagcgctgcccag-
caa-ctcg30), SREBP-1 (forward 50-gctcctccatcaatgacaaaatc-30;
reverse 50-gcttgagtttctggttgctgtgt-30; probe 50-aaggccatcgacta-
cattcgctttctgc-30), SREBP-2 (forward 50-cggtaaaatgatcacgccaaca-30;
reverse 50-ggtatatcaaaggctgctggat-30; probe 50-tcagcaccactccgca-
gacgagg-30) and GAPDH (forward 50-cacatggcctccaaggagtaa-30;
reverse 50-tgagggtctctctcttcctcttgt-30; probe 50-ctggaccaccag-
ccccagcaag-30). The comparative 2DCt (cycle threshold) method
was utilized for relative quantitation of STARD1 and STARD3mRNA,
and of ABCA1, PPARG, LXR, RXR, SREBP-1 and SREBP-2, were made
relative to GAPDHmRNA.
Macrophage cell lysates were prepared in RIPA buffer, supple-
mented with CompleteTM protease inhibitor cocktail. Proteins
(15–40 lg lane1) were separated by SDS–PAGE (NuPAGE, 10%
w/v gels), transferred to PDVF membrane and probed using anti-
STARD1 (1:1000), anti-STARD3 (1:1000) and anti-GAPDH
(1:2000) rabbit polyclonal antibodies. Detection was achieved
using anti-rabbit and anti-murine (above) secondary antibodies
(1:1000) and the ECL detection system [15]; densitometry was per-
formed using Scion Image software.
2.4. Statistical analyses
The number of independent experiments is indicated in the leg-
ends to ﬁgures; values shown are means ± S.E.M., with signiﬁcance
(P < 0.05) determined by Student’s t-test, or by repeated measures
ANOVA, followed by Dunnett’s or Tukey–Kramer post t-tests, as
appropriate; *P < 0.05; **P < 0.01 and ***P < 0.001 for the compari-
sons indicated.
3. Results and discussion
Amplicons (PCR) for both members of the STARD1 subfamily,
implicated in cholesterol transport, were sequenced (MRC Dun-
dee), conﬁrming 99.9% identity with the established gene sequence
for both gene products (NM_000349; NM_006804). Expression of
these genes was also detected in human peripheral blood mono-
cytes, and human heart aorta (unpublished data). Analysis of
STARD1 and STARD3 promoter regions revealed numerous putative
sites for regulation by lipid-responsive transcription factors
(SREBP, LXR and PPAR) (Fig. 1a). Within the region examined
(3 kb) a putative LXRE site was noted (743 to 767 bp), to-
gether with two putative PPAR/RXR response elements (482 to
Fig. 1. (a) Analysis of the 3kB promoter region of STARD1 and STARD3 for putative sites of regulation by lipid-responsive transcription factors (MatInspector). (b) Mass of
triacylglycerols, cholesterol and phospholipids and (c) incorporation of [14C]acetate into fatty acids, triacylglycerols, phospholipids, cholesterol and cholesteryl ester, during
differentiation of human (THP-1) monocytes into macrophages; values are mean ± S.E.M. of four independent experiments. (d) Expression of LXRa, PPARc, RXRa and SREBP-2
mRNA, relative to GAPDH; values are the means ± S.E.M. of 3–6 independent experiments. (e) Expression of ABCA1 mRNA and protein, relative to GAPDH, during
differentiation of human (THP-1) monocytes to macrophages; values are the means ± S.E.M. of three independent experiments. (f) Apo-AI speciﬁc efﬂux of [3H]cholesterol
from THP-1 macrophages, during differentiation; values are the means ± S.E.M. of three independent experiments. In all cases, *P < 0.05; **P < 0.01.
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STARD1, and some putative SREBP binding sites. By contrast, SREBP
binding sites were more numerous within the 3kB region of the
STARD3 promoter, and no putative LXRE was identiﬁed.
Signiﬁcant increases in lipid mass, and in Oil-Red-O staining
(Fig. 1b) were accompanied by decreases in cholesterol and lipid
biosyntheses, as judged by incorporation of [14C]acetate (Fig. 1c),
during phorbol-ester induced differentiation of human (THP-1)
monocytes to macrophages, reﬂecting distinct changes in cellular
phenotype and increases in lipid mass induced in the absence of
pharmacological intervention or exposure to modiﬁed lipopro-
teins. Gene expression of LXRa, RXRa, PPARc, SREBP-1 and
SREBP-2, transcription factors were measured during the differen-
tiation process (Fig. 1c). Temporal increases (P < 0.05) in steady-
state levels of mRNA of LXRa (days 1 and 7), PPARc (day 2),
RXRa (day 4) and SREBP-2 (days 1 and 7) were evident. How-
ever, levels of SREBP-1 (Fig. 1a and c) mRNA were considerably
lower (ratio to GAPDH mRNA: 0.22  103), at the limit of accu-
rate detection by Q-PCR (Ct > 38 cycles), and no induction of
SREBP-1 expression was noted at any stage of the differentiation
process. Macrophage differentiation was accompanied by markedincreases (12-fold; P < 0.05; n = 3) in protein expression of cho-
lesterol efﬂux transporter, ABCA1, relative to GAPDH (Fig. 1d)
and up-regulation of [3H]cholesterol efﬂux to apoAI (2.1-fold;
P < 0.05; n = 3) (Fig. 1e).
Quantitative PCR revealed signiﬁcant changes in gene expres-
sion of STARD1 and STARD3 (Fig. 2a): increases in steady-state lev-
els of STARD1 mRNA (1.6-fold; P < 0.05) were noted after four days
of differentiation, while STARD3 mRNA levels declined by 27%
(P < 0.04) over the same period, and by 47% (P < 0.01) at day 7. Cel-
lular content of STARD1 protein (37 kDa) increased during macro-
phage differentiation, signiﬁcantly and maximally at day 4 (3.98-
fold; P < 0.05; n = 3) and declined somewhat thereafter (Fig. 2b).
Levels of STARD3 protein (54 kDa) decreased during the same per-
iod, to around one-third of their initial value (P < 0.05; n = 3). Nota-
bly, levels of STARD1 protein were positively and signiﬁcantly
correlated with increases in macrophage cholesterol mass
(R2 = 0.84; P < 0.05) and with ABCA1 protein (R2 = 0.96; P < 0.01);
by contrast, levels of STARD3 protein correlated negatively with
cholesterol mass (R2 = 0.78; P < 0.05), but positively with incorpo-
ration of [14C]acetate into the free cholesterol pool (R2 = 0.97;
P < 0.001).
Fig. 2. (a and b) Expression of STARD1 and STARD3mRNA and protein, relative to GAPDH, during differentiation of THP-1 macrophages; values are the means ± S.E.M. of three
independent experiments. In all cases, *P < 0.05, **P < 0.01.
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methyl b-cyclodextrin (MCD; 10 mM, 1 h) (Fig. 3a), induced a com-
pensatory and marked increase (5.3-fold; P < 0.01) in cholesterolFig. 3. (a) Efﬂux of [3H]cholesterol to methyl b-cyclodextrin (MCD; 10 mM, 1 h), compare
independent experiments. (b) Synthesis of free cholesterol and cholesteryl ester, as judg
10 mM methyl b-cyclodextrin (1 h); values are the means ± S.E.M. of four independent
GAPDH, 24 h post-treatment with MCD (10 mM, 1 h); values are the means ± S.E.M. o
*P < 0.05; **P < 0.01; ***P < 0.001.biosynthesis over the next 24 h (Fig. 3b), resulting in macrophages
containing 35% less cholesterol mass than control cells (MCD
15.3 ± 1.9 mg cholesterol mg1 protein versus 23.4 ± 3.3 lg choles-d with serum-free RPMI 1640 medium alone; values are the means ± S.E.M. of three
ed by incorporation of [14C]acetate (24 h), and following treatment without, or with
experiments. (c) Expression of STARD1 and STARD3 mRNA and protein, relative to
f 3–6 independent experiments. In all cases, signiﬁcance values are as indicated:
F. Borthwick et al. / FEBS Letters 583 (2009) 1147–1153 1151terol mg1 protein; n = 5; P < 0.01). Under these conditions, 24 h
after treatment with MCD, levels of STARD1 mRNA decreased by
42% (P < 0.001), and levels of STARD1 protein decreased by 36%
(P < 0.01) (Fig. 3c and d). By contrast, steady-state levels of STARD3
mRNA increased 2.4-fold (P < 0.05) and STARD3 protein levels in-
creased by 2.7-fold (P < 0.05) compared with the control condition
(Fig. 3c and d). Inhibition of endogenous cholesterol biosynthesis,
using HMG CoA reductase inhibitor, lovastatin (10 lM; 24 h), sig-
niﬁcantly (P < 0.05) depleted the cholesterol content of THP-1 mac-
rophages by 38% (control 126.7 ± 28.4 lg cholesterol mg1 protein
versus lovastatin 78.0 ± 17.1 lg cholesterol mg1 protein; n = 5)
over a 24 h period. Under these conditions, STARD1 mRNA was re-
duced by 56% (ratio of mRNA to GAPDH mRNA: control
17.9 ± 2.9  103 versus lovastatin 7.8 ± 1.4  103; n = 3;
P < 0.001).
The abilities of agonists of LXR (T901317; 10 lM), RXR (9-cis-
retinoic acid; 5 lM), PPAR a (GW7647; 10 lM), PPARc (GW1929;
10 lM) and PPARd (GW0742; 10 lM) to inﬂuence gene and protein
expression of STARD1 and STARD3 were tested directly, and the re-
sults are shown in Fig. 4a and b. Signiﬁcantly, agonists of LXR,
PPARc and RXR all induced gene expression of STARD1 (P < 0.05);
PPARa and PPARd agonists did not alter steady-state levels of
STARD1 mRNA signiﬁcantly (Fig. 4a). By contrast, only retinoic
acid-induced gene expression of STARD3. All of the agonists used
induced signiﬁcant increases in gene expression of their common
downstream target, ABCA1 (Fig. 4b). Changes in gene expression
of STARD1 and STARD3 translated into signiﬁcant increases in
STARD1 protein in response to LXR and RXR ligands (Fig. 4c).
Since the addition of LXR agonist T0901317 also induced
expression of SREBP-1 mRNA by 4-fold in (ratio to GAPDH mRNA
0.08 ± 0.01  103 versus T0901317 0.33±0.08  103; P < 0.01;
n = 3), and because SREBP-2 expression was also induced during
macrophage differentiation (Fig. 1d), we considered the role ofFig. 4. (a) Gene expression of STARD1 and STARD3, and (b) ABCA1 mRNA, as judged by
protein, relative to GAPDH, following exposure to agonists of LXR (T0901317; 10 lM), PPA
(9-cis-retinoic acid; 5 lM) for 24 h. (d) Steady-state levels of STARD1 and STARD3 mRN
Values are the means ± S.E.M. of between 3 and 6 independent experiments; *P < 0.05; *SREBPs in regulation of STARD1 and STARD3 expression by utiliz-
ing the novel hypocholesterolaemic agent, LY295427 (20 lM).
LY295427 reverses the sequestration of SREBPs at the endoplasmic
reticulum by oxysterols, resulting in the up-regulation of SREBP-
target genes [16,29]. Under basal conditions, LY295427 signiﬁ-
cantly (P < 0.001) induced the expression of STARD1 by 13-fold,
and the expression of STARD3 nearly 10-fold (P < 0.001), arguing
that both genes can be targeted by SREBPs.
Finally, cholesterol loading, using acetylated LDL (50 lg ml1;
48 h) typically increased the cholesterol mass of THP-1 macro-
phages by 1.4-fold (53.0 ± 3.5 lg cholesterol mg1 cell protein ver-
sus 73.7 ± 14.4 lg cholesterol mg1 cell protein); similar increases
(1.45-fold; P < 0.05) were seen in the presence of the same concen-
tration of oxidized LDL (48 h). These pathophysiological conditions
led to decreases in gene expression of both STARD1 and STARD3,
relative to GAPDH (Fig. 5). Steady-state levels of STARD1mRNA de-
clined by 77–78% (P < 0.05) after exposure to both types of modi-
ﬁed lipoproteins. Treatment with acetylated LDL was
accompanied by a more modest decrease in steady-state levels of
mRNA encoding STARD3 (25%; P < 0.05), with a more marked
reduction in the presence of oxidized LDL (76%; P < 0.05).
Overall, the data suggest STARD1 (StAR) as a putative LXR and
RXR target in human macrophages, which is up-regulated in paral-
lel with macrophage ABCA1, and cholesterol efﬂux, during phor-
bol-ester induced differentiation, and repressed following acute
cholesterol depletion. These data agree well with studies in steroi-
dogenic tissues: Cummins et al. [17] have demonstrated that a
functional LXRE exists within the promoter region of STARD1 in
murine adrenal cortex; PPARc agonists, pioglitzaone and rosiglitz-
one up-regulate expression of StAR protein by 5–6-fold in human
ovarian cells [18] and both 9-trans and 9-cis-retinoic acid increase
StAR gene transcription in murine Leydig tumor cells [19]. Lipopro-
teins (LDL and HDL) increase the expression of StAR mRNA andsteady-state levels of mRNA relative to GAPDH mRNA, and (c) STARD1 and STARD3
Ra (GW7647; 10 lM), PPARd (GW0742; 10 lM), PPARc (GW1929; 10 lM) and RXR
A, relative to GAPDH mRNA, following treatment with LY295427 (20 lM) for 24 h.
*P < 0.01
Fig. 5. Gene expression of STARD1 and STARD3, as judged by steady-state levels of mRNA, following exposure to 50 lg ml1 of acetylated (a) or oxidized (b) LDL for 48 h.
Values are the means ± S.E.M. of ﬁve experiments; *P < 0.05.
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and 25-hydroxycholesterol also increase StAR mRNA and protein
in a time and dose-dependent manner in murine b.End3 endothe-
lioma cells [21]. Data published during preparation of this manu-
script, indicate that over-expression of StAR reduces macrophage
lipid accumulation, and inﬂammatory status, possibly by enhanc-
ing cholesterol trafﬁcking to CYP27A1 [12]. Thus, StAR appears to
be an integral ‘feed-forward’ element of the macrophage choles-
terol efﬂux pathway, activated by increases in sterol content
[22]. Ligation of LXR/RXR heterodimers increases StAR expression,
enhancing transport of cholesterol to mitochondrial CYP27A1,
amplifying the production of endogenous oxysterols and increas-
ing the expression of ABCA1 and/or ABCG1 [12,22].
Intriguingly, addition of the novel hypocholesterolaemic agent,
LY295427, which releases active SREBPs from the ER, also induced
the expression of STARD1. This data implies not only that one or
more of the putative SREs within the StAR promoter may be func-
tional, but also that endogenously produced oxysterols are pro-
duced in sufﬁcient amounts to sequester SREBPs under basal
conditions. Christenson et al. have reported that while both
SREBP-1a and SREBP-2 stimulate human StAR promoter activity,
SREBP-1a is more potent in this respect, and that the response is
conditional, being observed only in the presence of high levels of
SREBP-1a [30]. This response may represent a putative feedback
control mechanism, whereby increases in cholesterol biosynthesis
are accompanied by increased biosynthesis of oxysterols, via
CYP27A1, preventing excess cholesterol accumulating within the
cell (above). Thus, both LXRs and SREBPs may play a role in regu-
lation of macrophage STARD1 expression, as they do in steroido-
genic tissues [17,30], although we cannot rule out the possibility
that induction of SREBP-1c mediates the increases in STARD1
expression observed in response to LXR agonism. However, under
pathophysiological conditions, following expansion of macrophage
cholesterol mass, gene expression of STARD1 was profoundly re-
pressed. Loss of this physiological response, reported here for the
ﬁrst time, could therefore contribute to dysfunctional cholesterol
homeostasis and lipid accumulation in macrophage ‘foam cells’ [1].
By contrast, cellular increases in sterol content appear to down-
regulate STARD3 gene expression and vice versa. Steady-state lev-
els of STARD3 mRNA declined during macrophage differentiation
and cholesterol loading, and increased following acute cholesterol
depletion from the plasma membrane induced by methyl b-cyclo-
dextrin, and in response to the release of sequestered SREBPs by
LY295427. Certainly, the promoter region of STARD3 contains sev-
eral putative sites for regulation by SREBPs, transcription factors
transported from the ER to the Golgi, and activated by Golgi prote-
ases S1P and S2P, following decreases in cellular sterol content
[24]. STARD3 was also identiﬁed as one member of a group of
genes repressed by exposure to all-trans-retinoic acid (ATRA) in
H9 T-lymphoma cells [23], but was markedly up-regulated by 9-cis-retinoic acid in this study, suggesting isoform- or cell-type spe-
ciﬁc regulation of STARD3.
The STARD3 protein contains two cholesterol binding domains:
a cytoplasmic START domain and a conserved N-terminal MENTAL
(MLN64 N-terminal domain) region with four transmembrane
helices, responsible for targeting STARD3 to late endosomes
[13,25]. Over-expression of STARD3 in COS-1 cells enhances the fu-
sion of late endocytic organelles in an actin-dependent manner,
and stimulates the deposition of sterol in late endosomes contain-
ing this protein [14]. It is possible that the MENTAL domain may be
of importance in this regard, as abrogation of the STARD3 START
domain in mice induced only modest changes in phenotype [26].
However, it is also possible that cytosolic START proteins (STARD4
and STARD5) may have compensated for the loss of the STARD3
START domain in this ‘knockout’ study, to facilitate cholesterol
egress from late endosomes [6,7,13,14,25].
It has been argued that STARD1 and STARD3may serve a similar
purpose, as cleavage of the START domain from STARD3 produces a
protein fragment capable of mitochondrial cholesterol trafﬁcking
[27,28]. Thus, it is conceivable that functional redundancy allows
STARD3 mRNA and protein levels to decline as STARD1 mRNA
and protein levels increase: for example, it has been suggested that
the START domain of STARD3 may compensate for lack of STARD1
expression in placental tissues [27,28]. However, the modest
changes in phenotype observed in mice lacking the START domain
of STARD3maymake this rather unlikely [26]. Rather, STARD3may
be involved in trafﬁcking of endosomally derived cholesterol to the
endoplasmic reticulum, or to the plasma membrane; if the former,
STARD3 may help to increase the cholesterol content of that mem-
brane, and thus the retention of SREBPs by the SCAP/Insig-1 (-2)
complex [24]. Thus, STARD3 could contribute to the repression of
enzymes involved in cholesterol biosynthesis, the LDL receptor
and, possibly, STARD3 itself, and these possibilities are currently
under investigation. Alternatively, if STARD3 trafﬁcks choles-
terol to the plasma membrane, as do other endosomal choles-
terol-trafﬁcking proteins, such as Niemann Pick C-1 and -2
[31,32], it may facilitate the removal of cholesterol via ABCA1 or
ABCG1 proteins.
The results of this study reveal that STARD1 and STARD3 are dif-
ferentially regulated in macrophages during cholesterol depletion,
loading and following exposure to LXR and RXR agonists, and to
hypocholesterolaemic agent, L295427. These cholesterol-carrying
molecules, by virtue of their lipid binding domains, may offer sites
for therapeutic intervention in macrophage ‘foam cells’, and in the
etiology of atherosclerosis.
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